EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences. Select events (marked by *) will be webcasted live and webcast details will be available on the ‘Events’ page of Gritstone bio’s website: https://ir.gritstonebio.com/investors/events. Archived replays will be accessible for 30 days following each event.
23rd Annual Needham Virtual Healthcare Conference (Presentation*)
Date and Time: Tuesday, April 9, 2024 at 11:00am ET
Location: Virtual
Canaccord Genuity Horizons in Oncology Virtual Conference (Panel)
Panel Title: Cancer Vaccines – Building on Recent Learnings
Date and Time: Monday, April 15, 2024 at 11:00am ET
Location: Virtual
Cambridge Healthtech Institute’s Immuno-Oncology Summit Europe (Presentation)
Presentation Title: Clinical Trial Results with a Personalised Neoantigen Vaccine in a Cold Tumour—Can We Bring the Heat?
Date and Time: Wednesday, April 24, 2024 at 9:05am BST
Location: London, UK
7th International Neoantigen Summit (Presentation)
Panel Title: Clinical Trial Data with a Personalised Neoantigen Cancer Vaccine in Metastatic
Colorectal Cancer
Panel Date and Time: Tuesday, April 30, 2024 at 12:30pm CEST
Location: Amsterdam, Netherlands
PEGS BOSTON (Panel)
Panel Title: Personalized Cancer Vaccines - Where are They Going Now?
Date and Time: Monday, May 13, 2024 at 9:00am ET
Location: Boston, MA
Citizens JMP Life Sciences Conference (Fireside Chat*)
Date and Time: Tuesday, May 14, 2024 at 10:30am ET
Location: New York, NY
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Contacts
Investors:
George E. MacDougall
Gritstone bio, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Dan Budwick
1AB
(973) 271-6085
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.03 |
| Daily Volume: | 0 |
| Market Cap: | US$3.800M |
September 30, 2024 August 13, 2024 May 09, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
